文献速递毛发、甲与色素性疾病

利特昔替尼治疗斑秃的临床应答模式:ALLEGRO项目分析

Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2025-02-17

该事后分析评估了191例接受利特昔替尼50 mg治疗的斑秃患者(≥12岁,头皮脱发≥50%)的SALT评分轨迹至第24个月。45.5%为应答者(SALT≤20),其中93.1%维持应答,46.0%达到完全缓解;女性、脱发范围较小和病程较短与治疗应答相关。

要点

  • 约45%患者SALT≤20,其中93.1%维持应答,46.0%达完全缓解。
  • 最高11%患者需超过1年治疗才达到应答,提示延长疗程的重要性。
  • 女性、脱发范围较小和病程较短与治疗应答相关。

核心结论

  • 约45%患者为SALT评分应答者,其中93.1%维持应答,46.0%达到完全缓解。
  • 最高11%患者需超过1年利特昔替尼治疗才达到应答,强调延长治疗时长的重要性。

研究设计与样本

  • 事后分析评估从2b/3期研究滚动进入ALLEGRO-LT研究的患者,接受利特昔替尼50 mg每日一次。
  • 纳入年龄≥12岁、头皮脱发≥50%的患者,共191例接受利特昔替尼50 mg治疗。
  • 按SALT评分轨迹至第24个月分类为早期、中期、晚期应答者或部分应答者、复发者、无应答者。

主要发现

  • 191例中87例(45.5%)为应答者(SALT≤20),24例(12.6%)为部分应答者,24例(12.6%)为复发者,56例(29.3%)为无应答者。
  • 87例应答者中81例(93.1%)维持临床应答,47例(46.0%)达到完全缓解(SALT=0至少1次)。
  • 与治疗应答相关的因素包括女性、脱发范围较小和脱发病程较短。

关键数值与推荐

  • 应答者定义为SALT评分≤20;部分应答者维持30%改善;复发者达到但未维持30%改善;无应答者未达到30%改善。
  • 持续应答定义为达到并维持SALT≤20至第24个月所有后续可用时间点;完全缓解定义为至第24个月至少1次SALT=0。

临床怎么用

  • 利特昔替尼50 mg治疗斑秃约45%患者可达SALT≤20,多数应答者可维持应答。
  • 部分患者需超过1年治疗才达到应答,临床应延长治疗时长以评估疗效。
  • 女性、脱发范围较小和病程较短的患者更可能对治疗应答。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ritlecitinib, an oral JAK3/TEC family kinase inhibitor, demonstrated efficacy over 48 weeks in patients with alopecia areata (AA) in the ALLEGRO phase 2b/3 study. OBJECTIVES: This post hoc analysis evaluated individual Severity of Alopecia Tool (SALT) score trajectories in patients who received ritlecitinib 50 mg and rolled over from Phase 2b/3 into the ongoing, open-label, Phase 3 ALLEGRO-LT study to describe long-term response patterns and associated baseline disease characteristics. METHODS: Patients aged ≥12 years with ≥50% scalp hair loss received ritlecitinib 50 mg once daily in both studies. SALT score trajectories from baseline to Month 24 were used to categorise patients as early (SALT score ≤20 at Week 24 and Months 12 and 24), middle (≤20 at Months 12 and 24) or late responders (≤20 by Month 24) or as partial responders (maintained 30% improvement), relapsers (achieved but did not maintain 30% improvement) or non-responders (did not achieve 30% improvement). The proportions of patients achieving sustained response (achieved and maintained SALT score ≤20 at all subsequent available time points through Month 24) and complete response (SALT score 0 at ≥1 time point through Month 24) were evaluated. Multivariable logistic regression assessed variables associated with response. RESULTS: Of 191 patients treated with ritlecitinib 50 mg, 87 (45.5%) were responders (SALT score ≤20), 24 (12.6%) were partial responders, 24 (12.6%) were relapsers and 56 (29.3%) were non-responders. Of 87 patients categorised as responders, 81 (93.1%) sustained their clinical response and 47 (46.0%) achieved complete response. Factors associated with treatment response included female sex and less extensive and shorter duration of hair loss. CONCLUSIONS: Approximately 45% of patients were SALT score responders, with up to 11% requiring >1 year of ritlecitinib treatment to achieve response, highlighting the importance of extended treatment duration. GOV REGISTRATION: ALLEGRO phase 2b/3 study (NCT03732807); ALLEGRO-LT study (NCT04006457).

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. King B, Mirmirani P, Lo Sicco K, et al. Patterns of clinical response in patients with alopecia areata treated with ritlecitinib in the ALLEGRO clinical development programme. J Eur Acad Dermatol Venereol. 2025. PMID: 39962358. doi:10.1111/jdv.20547

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。